Richmond Pharmacology is pleased to share that we will be presenting at the Safety Pharmacology Society Annual Meeting (SPS 2025), taking place from 13–15 October.
Representing Richmond Pharmacology at SPS 2025:
· Miquel Serna Pascual, Postdoctoral Researcher (Richmond Pharmacology & King’s College London)
Miquel will present findings from Richmond’s research collaboration with Professor Jitesh Nandi at King’s College London, focused on identifying safety signals in early-phase clinical trials and advancing cardiac safety methodologies through refined ECG processing techniques.
At SPS 2025, we look forward to contributing to discussions around:
· Enhancing cardiac safety assessments in early-phase trials
· Precision ECG processing and interpretation
· Translating digital cardiac biomarkers into regulatory-ready endpoints
· Collaborative academic–industry models accelerating innovation in safety pharmacology
· Data-driven approaches to signal detection in first-in-human studies
About SPS 2025
The Safety Pharmacology Society Annual Meeting is a global forum bringing together leaders in drug discovery and safety pharmacology to advance the evaluation of new drugs and chemicals through cutting-edge science and collaboration.
If you are attending SPS 2025 and would like to learn more about Richmond’s work in cardiac safety and early-phase study design, please contact us:
info@richmondresearchinstitute.org
Learn more: SPS2025 | Safety Pharmacology Society Annual Meeting
Richmond Research Institute will participate in The Liver Meeting 2025 in Washington, DC, represented by Chief Scientific Officer James Rickard. The team will discuss early-phase hepatology trials, non-invasive biomarkers, regulatory...
Richmond Research Institute to present key cardiology research at Heart Failure 2025 in Belgrade, Serbia.
The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and...
We studied the cardiac safety of P218 using advanced QTc assessments and found doses of up to 1000mg do not prolong the QTc suggesting a low risk of drug induced arrhythmia.
12-lead resting ECGs are considered essential in clinical trials, but their limitations have led to increasing use of 12-lead Holter monitor devices.
Dr. Taubel explains to the New Scientist why patient safety is pivotal in phase I trials